349 related articles for article (PubMed ID: 28892090)
1. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.
He X; Riceberg J; Soucy T; Koenig E; Minissale J; Gallery M; Bernard H; Yang X; Liao H; Rabino C; Shah P; Xega K; Yan ZH; Sintchak M; Bradley J; Xu H; Duffey M; England D; Mizutani H; Hu Z; Guo J; Chau R; Dick LR; Brownell JE; Newcomb J; Langston S; Lightcap ES; Bence N; Pulukuri SM
Nat Chem Biol; 2017 Nov; 13(11):1164-1171. PubMed ID: 28892090
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
Yang Y; Xia Z; Wang X; Zhao X; Sheng Z; Ye Y; He G; Zhou L; Zhu H; Xu N; Liang S
Mol Pharmacol; 2018 Aug; 94(2):885-894. PubMed ID: 29784649
[TBL] [Abstract][Full Text] [Related]
3. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
4. The post-translational modification, SUMOylation, and cancer (Review).
Han ZJ; Feng YH; Gu BH; Li YM; Chen H
Int J Oncol; 2018 Apr; 52(4):1081-1094. PubMed ID: 29484374
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.
He X; Riceberg J; Pulukuri SM; Grossman S; Shinde V; Shah P; Brownell JE; Dick L; Newcomb J; Bence N
PLoS One; 2015; 10(4):e0123882. PubMed ID: 25860128
[TBL] [Abstract][Full Text] [Related]
6. SUMOylation code in cancer development and metastasis.
Kim KI; Baek SH
Mol Cells; 2006 Dec; 22(3):247-53. PubMed ID: 17202851
[TBL] [Abstract][Full Text] [Related]
7. SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene.
Wang CM; Brennan VC; Gutierrez NM; Wang X; Wang L; Yang WH
J Cell Biochem; 2013 Mar; 114(3):589-98. PubMed ID: 22991139
[TBL] [Abstract][Full Text] [Related]
8. Sumoylation and Its Contribution to Cancer.
Lee JS; Choi HJ; Baek SH
Adv Exp Med Biol; 2017; 963():283-298. PubMed ID: 28197919
[TBL] [Abstract][Full Text] [Related]
9. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
Langston SP; Grossman S; England D; Afroze R; Bence N; Bowman D; Bump N; Chau R; Chuang BC; Claiborne C; Cohen L; Connolly K; Duffey M; Durvasula N; Freeze S; Gallery M; Galvin K; Gaulin J; Gershman R; Greenspan P; Grieves J; Guo J; Gulavita N; Hailu S; He X; Hoar K; Hu Y; Hu Z; Ito M; Kim MS; Lane SW; Lok D; Lublinsky A; Mallender W; McIntyre C; Minissale J; Mizutani H; Mizutani M; Molchinova N; Ono K; Patil A; Qian M; Riceberg J; Shindi V; Sintchak MD; Song K; Soucy T; Wang Y; Xu H; Yang X; Zawadzka A; Zhang J; Pulukuri SM
J Med Chem; 2021 Mar; 64(5):2501-2520. PubMed ID: 33631934
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
Hua D; Wu X
Eur J Med Chem; 2022 Apr; 233():114227. PubMed ID: 35247754
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review).
Zhou Y; Ji C; Cao M; Guo M; Huang W; Ni W; Meng L; Yang H; Wei JF
Int J Mol Med; 2018 Jan; 41(1):3-12. PubMed ID: 29115401
[TBL] [Abstract][Full Text] [Related]
12. The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis C; Hassan Z; Schick M; Keller U; Schneider G
Br J Cancer; 2021 Feb; 124(3):531-538. PubMed ID: 33071285
[TBL] [Abstract][Full Text] [Related]
13. A differential requirement for SUMOylation in proliferating and non-proliferating cells during Drosophila development.
Kanakousaki K; Gibson MC
Development; 2012 Aug; 139(15):2751-62. PubMed ID: 22745316
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive compilation of SUMO proteomics.
Hendriks IA; Vertegaal AC
Nat Rev Mol Cell Biol; 2016 Sep; 17(9):581-95. PubMed ID: 27435506
[TBL] [Abstract][Full Text] [Related]
15. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein.
Schimmel J; Eifler K; Sigurðsson JO; Cuijpers SA; Hendriks IA; Verlaan-de Vries M; Kelstrup CD; Francavilla C; Medema RH; Olsen JV; Vertegaal AC
Mol Cell; 2014 Mar; 53(6):1053-66. PubMed ID: 24582501
[TBL] [Abstract][Full Text] [Related]
16. Sumoylation on its 25th anniversary: mechanisms, pathology, and emerging concepts.
Celen AB; Sahin U
FEBS J; 2020 Aug; 287(15):3110-3140. PubMed ID: 32255256
[TBL] [Abstract][Full Text] [Related]
17. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2.
Hirohama M; Kumar A; Fukuda I; Matsuoka S; Igarashi Y; Saitoh H; Takagi M; Shin-ya K; Honda K; Kondoh Y; Saito T; Nakao Y; Osada H; Zhang KY; Yoshida M; Ito A
ACS Chem Biol; 2013 Dec; 8(12):2635-42. PubMed ID: 24143955
[TBL] [Abstract][Full Text] [Related]
18. Viral control of the SUMO pathway: Gam1, a model system.
Chiocca S
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1419-21. PubMed ID: 18031235
[TBL] [Abstract][Full Text] [Related]
19. T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Lam V; Roleder C; Liu T; Bruss N; Best S; Wang X; Phillips T; Shouse G; Berger AJ; Alinari L; Wang L; Siddiqi T; Pennock ND; Danilov AV
Mol Cancer Ther; 2023 Sep; 22(9):1040-1051. PubMed ID: 37420267
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of Arabidopsis thaliana SUMO pathways in E. coli: functional evaluation of SUMO machinery proteins and mapping of SUMOylation sites by mass spectrometry.
Okada S; Nagabuchi M; Takamura Y; Nakagawa T; Shinmyozu K; Nakayama J; Tanaka K
Plant Cell Physiol; 2009 Jun; 50(6):1049-61. PubMed ID: 19376783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
